Longevity & Healthspan

Longevity & Healthspan

Populations are ageing faster than health systems were built to absorb, and the cost of that gap falls on governments, employers and families alike. This sector, the flagship theme of the Global Investors Forum, examines how capital, science and policy can extend the years people live in good health rather than the years they simply live. It treats the biology of ageing as an investable field with clinical evidence, regulatory pathways and commercial timelines attached.

‍

The Cost of the Healthspan Gap

Life expectancy has risen across most of the world, but the years gained have not all been healthy ones. The distance between how long people live and how long they live well runs to several years in most advanced health systems, and it carries the weight of chronic disease, lost productivity and long-term care. The investment case has moved accordingly, from treating illness late toward compressing the years of ill health and intervening before decline becomes irreversible.

‍

Key Thematic Areas

• Biology of ageing and cellular senescence
• Biomarkers, ageing clocks and biological age measurement
• Longevity therapeutics and drug repurposing
• Regulatory pathways and clinical endpoints for healthspan
• The economics of longer working lives and later-life care
• Convergence with regenerative, diagnostic and preventive science

‍

Features & Activities

• Trend Panels – the science, economics and policy of longer healthy lives.
• Deal Room – meetings arranged around live transactions: financing rounds, licensing terms and co-investment commitments.
• Scientific Roundtables – closed sessions on trial design and ageing endpoints.
• Innovation Showcase – diagnostics, therapeutics and clinical platforms in demonstration.
• Pitch Stage – short slots for founders in therapeutics, diagnostics and care delivery.

‍

Who Will You Meet?

• Geroscience researchers and clinical trial designers
• Longevity clinic founders and care delivery operators
• Life insurers, reinsurers and annuity providers
• Pension funds and long-duration institutional allocators
• National ageing strategy leads and public health officials
• Employers and occupational health purchasers

‍

The Future of Longevity Investment

• Measurable Ageing – validated biomarkers turn healthspan into a trackable clinical endpoint.
• Preventive Care Models – reimbursement shifts toward keeping people well rather than treating them late.
• AI in Discovery – machine learning shortens the path from ageing target to candidate molecule.
• Consumer Longevity – clinics, diagnostics and nutrition build a retail market alongside clinical research.
• Institutional Capital – long-duration allocators treat healthy ageing as a hedge against demographic liabilities.
• Category Definition – longevity moves from an adjacent interest to a named allocation with its own mandates and benchmarks.

‍

Key Benefits

• Transaction Readiness – meetings with companies that arrive with clinical data and defined funding needs.
• Scientific Grounding – claims tested against clinical evidence rather than marketing language.
• Regulatory Foresight – advance understanding of how ageing is being treated as an addressable condition.
• Portfolio Diversification – exposure to a theme driven by demographics rather than market cycles.
• Long-Horizon Partnerships – co-investment relationships built around multi-year clinical timelines.